Home › To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher
 

Keywords :   


To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher

2015-03-18 21:42:25| Biotech - Topix.net

Martine Rothblatt is the CEO of United Therapeutics Corp., which recently received Food and Drug Administration approval for its drug, Unituxin for treating pediatric patients with high-risk neuroblastoma. It also received a voucher that can be used to fast track a drug through the FDA's regulatory process.

Tags: united sell potential choice

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.05New Febreze Car Dials Up the Intensity in Automotive Air Care
02.05Monadnock Paper Mills appoints Chloe Jones
02.05The insect farmers turning to AI to help lower costs
01.05Knowing beats hoping
01.05Anderson & Vreeland acquires Adheso-Graphics
01.05Brazil issues favorable regulatory determination for PICs PRRS-resistant pig
01.05Fed holds key interest rate and warns on inflation
01.05Axalta Releases First Quarter 2024 Results
More »